🇺🇸 FDA
Patent

US 10875912

EGFL6 specific monoclonal antibodies and methods of their use

granted A61KA61K2039/505A61K9/0019

Quick answer

US patent 10875912 (EGFL6 specific monoclonal antibodies and methods of their use) held by The Board of Regents of the University of Texas System expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/505, A61K9/0019, A61P, A61P35/00